Daratumumab
- Generic Name
- Daratumumab
- Brand Names
- Darzalex, Darzalex Faspro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 945721-28-8
- Unique Ingredient Identifier
- 4Z63YK6E0E
- Background
Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.
...
- Indication
Daratumumab is indicated as an intravenous injection alone or in combination with other medications for the treatment of multiple myeloma. It is available as a combination product with hyaluronidase for the treatment of adults with multiple myeloma as monotherapy or combination therapy and light chain amyloidosis in combination with other drugs.
- Associated Conditions
- Multiple Myeloma (MM), Primary Amyloidosis, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
- Associated Therapies
- -
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
- Conditions
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 34
- Registration Number
- NCT05308654
- Locations
- 🇺🇸
Tulane University School of Medicine /ID# 244854, New Orleans, Louisiana, United States
🇺🇸American Oncology Partners of Maryland /ID# 244858, Bethesda, Maryland, United States
🇺🇸Atrium Health Levine Cancer Institute /ID# 243420, Charlotte, North Carolina, United States
Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 96
- Registration Number
- NCT05284591
- Locations
- 🇩🇪
Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Hessen, Germany
A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 36
- Registration Number
- NCT05280275
- Locations
- 🇬🇷
Anticancer Hospital of Thessaloniki "Theageneio", Thessaloniki, Greece
🇬🇷Department of Clinical Therapeutics, School of Medicine, National Kapodistrian University of Athens (NKUA), Athens, Greece
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- TeneoOne Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT05259839
- Locations
- 🇺🇸
University of Massachusetts - Worcester /ID# 243977, Worcester, Massachusetts, United States
🇺🇸University of Texas Southwestern Medical Center /ID# 243273, Dallas, Texas, United States
🇦🇺Fiona Stanley Hospital /ID# 244753, Murdoch, Western Australia, Australia
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 750
- Registration Number
- NCT05257083
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UC San Diego Health Moores Cancer Center, San Diego, California, United States
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2022-02-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 150
- Registration Number
- NCT05250973
- Locations
- 🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇬🇧University College Hospital, London, United Kingdom
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05243342
- Locations
- 🇪🇸
Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
🇦🇺Alfred Hospital, Melbourne, Victoria, Australia
🇩🇰Sygehus Lillebælt, Vejle, Vejle, Denmark
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 100
- Registration Number
- NCT05218603
- Locations
- 🇪🇸
Hospital Quirón Sagrado Corazón, Barcelona, Spain
🇪🇸Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín, Las Palmas De Gran Canaria, Spain
🇪🇸Hospital Ruber Juan Bravo 39, Madrid, Spain
FT576 in Subjects With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 31
- Registration Number
- NCT05182073
- Locations
- 🇺🇸
Texas Oncology-Medical City Dallas, Dallas, Texas, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Virginia Oncology Associates, Norfolk, Virginia, United States
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 317
- Registration Number
- NCT05137054
- Locations
- 🇺🇸
Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.